Lexology August 12, 2024
Global Competition Review

Megan Browdie, Kathy O’Neill, Anna Caro and Amanda Griggs, Cooley LLP

This is an extract from the 2025 edition of the Americas Antitrust Review published by Global Competition Review. The whole publication is available here.

This is an Insight article, written by a selected partner as part of GCR’s co-published content. Read more on Insight

In summary

The technology and life sciences industries continue to be front of mind at the US Department of Justice and the Federal Trade Commission and the focus of significant enforcement efforts. Armed with the recently released merger guidelines, and no guarantee of a second term, Biden antitrust enforcers are swinging for the fences in 2024 with an aggressive approach to merger enforcement that will...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Govt Agencies, Mergers & Acquisitions / JV, Pharma, Pharma / Biotech, Technology, Trends
Three ways the Trump administration could reinvest in rural America's future, starting with health care
Healthcare data breaches down in '24
Drugmakers prep for bird flu outbreak, despite continued low risk
How AI, Tech, And Policy Can Stop The Wildfire Crisis
Bird flu crisis enters new phase

Share This Article